-
ClinicoEconomics and Outcomes Research
- About Dovepress
Open access peer-reviewed scientific and medical journals.
- Open Access
Dove Medical Press is now a member of the Open Access Initiative
- An Author's Guide
A guide to help authors get their paper published.
- Advocacy
Support Open Access and Dove Press
- Reprints
Promotional Article Monitoring - further details
- Favored Author Program
Real benefits for authors, including fast-track processing of papers.
The economic impact of enoxaparin versus unfractionated heparin for prevention of venous thromboembolism in acute ischemic stroke patients
Review
(3683) Total Article Views
Authors: Pineo GF, Lin J, Annemans L
Published Date April 2012 Volume 2012:4 Pages 99 - 107
DOI: http://dx.doi.org/10.2147/CEOR.S30857
Received: | 14 February 2012 |
---|---|
Accepted: | 15 March 2012 |
Published: | 23 April 2012 |
1Department of Medicine, University of Calgary, Calgary, Alberta, Canada; 2Novosys Health, Flemington, NJ; 3Department of Medicine, Ghent University, Ghent and Brussels University, Brussels, Belgium
Abstract: Venous thromboembolism (VTE) is a common complication after acute ischemic stroke that can be prevented by the use of anticoagulants. Current guidelines from the American College of Chest Physicians recommend that patients with acute ischemic stroke and restricted mobility receive prophylactic low-dose unfractionated heparin or a low-molecular-weight heparin. Results from clinical studies, most recently from PREVAIL (PREvention of Venous Thromboembolism After Acute Ischemic Stroke with LMWH and unfractionated heparin), suggest that the low-molecular-weight heparin, enoxaparin, is preferable to unfractionated heparin for VTE prophylaxis in patients with acute ischemic stroke and restricted mobility. This is due to a better clinical benefit-to-risk ratio, with the added convenience of once-daily administration. In line with findings from modeling studies and real-world data in acutely ill medical patients, recent economic data indicate that the higher drug cost of enoxaparin is offset by the reduction in clinical events as compared with the use of unfractionated heparin for the prevention of VTE after acute ischemic stroke, particularly in patients with severe stroke. With national performance measures highlighting the need for hospitals to examine their VTE practices, the relative costs of different regimens are of particular importance to health care decision-makers. The data reviewed here suggest that preferential use of enoxaparin over unfractionated heparin for the prevention of VTE after acute ischemic stroke may lead to reduced VTE rates and concomitant cost savings in clinical practice.
Keywords: acute ischemic stroke, cost savings, enoxaparin, unfractionated heparin, venous thromboembolism
Post to:
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter
Readers of this article also read:
- Testimonials
"I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University.
- Reliability and validity of the Mywellness Key physical activity monitor
- Evidence-based decision-making within the context of globalization: A “Why–What–How” for leaders and managers of health care organizations
- "Globalized public health.” A transdisciplinary comprehensive framework for analyzing contemporary globalization’s influences on the field of public health
- Hepatitis C virus infection and risk of cancer: a population-based cohort study